Madrigal Pharmaceuticals (MDGL) Retained Earnings (2010 - 2026)
Madrigal Pharmaceuticals (MDGL) posted quarterly Retained Earnings of -$2.2 billion for Q2 2026, down 16.95% year-over-year from -$2.7 billion in Q2 2025, and down 2.65% quarter-over-quarter from -$2.2 billion in Q1 2026.
Madrigal Pharmaceuticals (MDGL) Retained Earnings (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported Retained Earnings for 17 consecutive years, with -$2.2 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Retained Earnings fell 16.95% year-over-year to -$2.2 billion; the TTM figure through Jun 2026 stood at -$2.2 billion (down 16.95% YoY), while the FY2025 annual figure was -$2.1 billion, down 16.0% from the prior year.
- Retained Earnings declined to -$2.2 billion in Q2 2026 per MDGL's latest filing, from -$2.2 billion in the prior quarter.
- Across five years, Retained Earnings topped out at -$724.8 million in Q1 2022 and bottomed at -$2.2 billion in Q2 2026.
- Historically, Retained Earnings has averaged -$1.5 billion across 5 years, with a median of -$1.6 billion in 2024.
- Annual changes were most pronounced in 2022 — Retained Earnings tumbled 51.63% — and 2025, when it decreased 16.0%.
- Madrigal Pharmaceuticals' Retained Earnings stood at -$962.7 million in 2022, then sank by 38.81% to -$1.3 billion in 2023, then slumped by 34.86% to -$1.8 billion in 2024, then fell by 16.0% to -$2.1 billion in 2025, then declined by 7.29% to -$2.2 billion in 2026.
- Business Quant data shows MDGL's Retained Earnings at -$2.2 billion in Q2 2026, -$2.2 billion in Q1 2026, and -$2.1 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Madrigal Pharmaceuticals | 14.79 Bn | 13.95 Bn | - | -2.24 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.24 Bn |
| Mar 31, 2026 | -2.18 Bn |
| Dec 31, 2025 | 873,000.00 |
| Sep 30, 2025 | 1.07 Mn |
| Jun 30, 2025 | -1.92 Bn |
| Mar 31, 2025 | 389,000.00 |
| Dec 31, 2024 | 468,000.00 |
| Sep 30, 2024 | -1.74 Bn |
| Jun 30, 2024 | -1.64 Bn |
| Mar 31, 2024 | -1.48 Bn |
| Dec 31, 2023 | -1.34 Bn |
| Sep 30, 2023 | -1.22 Bn |
| Jun 30, 2023 | -1.13 Bn |
| Mar 31, 2023 | -86,000.00 |
| Dec 31, 2022 | -32,000.00 |
| Sep 30, 2022 | -876.76 Mn |
| Jun 30, 2022 | -447,000.00 |
| Mar 31, 2022 | -402,000.00 |
| Dec 31, 2021 | -80,000.00 |
| Sep 30, 2021 | -602.76 Mn |